CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Legal Officer sold 2,296 shares at an average $28.02 ($64,343)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Legal Officer sold 7,500 shares at an average $24.82 ($186,136)
- 4 Open-market buy Chief Executive Officer bought 4,000 shares at $25.37 ($101,479)
- 4 Open-market buy Chief Executive Officer bought 5,500 shares at $29.15 ($160,324)
- 4 Open-market sale General Counsel and Secretary sold 29,971 shares at $29.07 ($871,257)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 250,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4/A Open-market sale Chief Executive Officer sold 50,000 shares at $36.80 ($1,840,000)
- 4 Open-market sale Chief Executive Officer sold 50,000 shares at $36.80 ($1,840,000)
- 4 Open-market sale General Counsel and Secretary sold 6,843 shares at $35.66 ($244,021)
Page 4 of 14 · 264 filings